Career
Since 2020 | Chairman Comprehensive Cancer Center Zurich (CCCZ |
---|---|
2018-2020 | President Swiss Society of Hematology |
Since 2018 | Chairman and Director Department of Medical Oncology and Hematology University Hospital Zürich |
Since 2010 |
Professor with right to confer doctorate at the Mathematical and Natural Sciences Faculty at the University of Zürich |
Since 2009 |
Professor/Ordinarius of Hematology at the Medical Faculty and Director Hematology at the University and University Hospital of Zürich, Switzerland |
2009 | Diploma Hematology, Switzerland (FMH) |
2009 | Diploma Internal Medicine, Switzerland (FMH) |
2007 | Habilitation (Venia Legendi in Internal Medicine), University of Tuebingen Medical School, Germany |
2007 | Diploma Hematology and Oncology, Germany/European Union |
2006 | Diploma Internal Medicine, Germany/European Union |
2002-2009 | Research Group Leader, Institute for Research in Biomedicine (IRB), Switzerland; continuation of medical training at Internal Medicine and Hematology and Oncology, University Hospital Tübingen, Germany, and Swiss-Italian Institute for Oncology (IOSI), Bellinzona, Switzerland |
1999-2002 | Postdoctoral Research Fellow, Stanford Univerrsity |
1995-1999 | Clinical training Internal Medicine and Hematology and Oncology, University Hospital Tübingen |
1996 | MD Thesis (Dissertation) University of Tuebingen, Germany |
1995 | MD University of Tuebingen, Germany |
Most important Memberships
- Swiss Society of Hematology (SSH)
- Swiss Medical Association (FMH)
- Swiss Society for Allergology and Immunology (SSAI)
- Swiss Stem Cell Network (SSCN)
- German Society of Hematology and Oncology (DGHO)
- European Society of Hematology (EHA)
- American Society of Hematology (ASH)
- International Society of Experimental Hematology (ISEH)
- Henry Kunkel Society (HKS)
- Charles Rodolphe Brupbacher Foundation (scientific committee)
- Helmut Horten Foundation (scientific committee)
Research Focus
- Hematopoietic Stem Cells, Hematopoiesis, Hematopoietic Ageing
- Hematopoietic Stem Cell Malignancies (AML, MDS, MPN)
- Immunotherapy of Cancer